

AICAR Catalog No: tcsc1951

 \checkmark Available SizesSize: 50mgSize: 100mgSize: 200mgSize: 500mgSize: 500mgSize: 1gSize: 2g \checkmark SpecificationsCAS No:
2627-69-2Formula:
 $c_gH_14N_4O_5$

Pathway:

Target:

Autophagy;AMPK;AMPK;Mitophagy

Purity / Grade:

>98%

Solubility:

H2O : 65 mg/mL (251.71 mM; Need ultrasonic and warming); DMSO : \geq 30 mg/mL (116.18 mM)

Alternative Names:

Acadesine; AICA Riboside

Copyright 2021 Taiclone Biotech Corp.



Observed Molecular Weight:

258.23

Product Description

AICAR is an activator of AMP-activated protein kinase (AMPK), down-regulates the insulin receptor expression in HepG2 cells.

IC50 & Target: AMPK^[1]

In Vitro: HepG2 cells are treated with various concentrations of AICAR (0.1-1.0 mM) for 12, 24, and 48 h, respectively. The expression level of IR- β significantly decreases with 0.25, 0.5, and 1.0 mM of AICAR at 48 h to 50%, 53%, and 46% of the control, respectively^[1].

In Vivo: Fourteen-week-old male, lean (L; 31.3 g body wt) wild-type andob/ob (O; 59.6 g body wt) mice are injected with the AMP-activated kinase (AMPK) activator AICAR (A) at 0.5 mg/g per day or saline control (C) for 14 days. At 24 h after the last injection (including a 12-h fast), all mice are killed, and the plantar flexor complex muscle (gastrocnemius, soleus, and plantaris) is excised for analysis. Muscle mass is lower in OC (159±12 mg) than LC, LA, and OA (176±10, 178±9, and 166±16 mg, respectively) mice, independent of a body weight change^[2]. The kidney weight is significantly higher in the untreated group when compared with both the exercise and AICAR (0.5 mg/g body wt) groups. The heart weight is higher in the exercise group than in the other groups, whereas the liver weight is significantly higher in the AICAR-treated group when compared with the exercise and untreated groups^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.